Summary
This 8-K filing from Boston Scientific Corporation (BSX) reports on the outcome of a legal dispute with Channel Medsystems, Inc. (Channel) concerning a terminated acquisition agreement. The Delaware Chancery Court ruled on December 18, 2019, that Boston Scientific was not entitled to terminate the agreement and must proceed with the acquisition of Channel as per an order of specific performance. This decision means Boston Scientific is likely obligated to acquire Channel, which could involve upfront payments and contingent payments as originally outlined in the agreement. The company is currently evaluating its options in response to this court ruling. Investors should be aware of the potential financial implications of this mandatory acquisition, including the previously disclosed potential payment of $145 million cash up-front and up to $130 million in contingent payments. The outcome of Boston Scientific's evaluation and any subsequent actions will be critical to monitor for understanding the full impact on the company's financial position and strategic direction.
Key Highlights
- 1Delaware Chancery Court ruled Boston Scientific must proceed with the acquisition of Channel Medsystems, Inc.
- 2The court found Boston Scientific was not entitled to terminate the acquisition agreement.
- 3Channel Medsystems is entitled to an order of specific performance requiring Boston Scientific to close the merger.
- 4Boston Scientific is currently evaluating its options following the court's decision.
- 5The original agreement involved a potential $145 million cash up-front payment and up to $130 million in contingent payments.
- 6Channel Medsystems received FDA approval for its Cerene™ Cryotherapy Device in April 2019.